Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.
about
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatristsEfficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.Practitioner review: Long-term pharmacological treatment of pediatric bipolar disorder.Practical pharmacotherapy for acute schizophrenia patients.Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
P2860
Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety, tolerability, and effi ...... pen-label, continuation study.
@en
Safety, tolerability, and effi ...... pen-label, continuation study.
@nl
type
label
Safety, tolerability, and effi ...... pen-label, continuation study.
@en
Safety, tolerability, and effi ...... pen-label, continuation study.
@nl
prefLabel
Safety, tolerability, and effi ...... pen-label, continuation study.
@en
Safety, tolerability, and effi ...... pen-label, continuation study.
@nl
P2093
P2860
P356
P1476
Safety, tolerability, and effi ...... pen-label, continuation study.
@en
P2093
Melissa DelBello
Robert L Findling
Sanjeev Pathak
Sherry Liu
Willie R Earley
P2860
P304
P356
10.1089/CAP.2012.0092
P577
2013-09-11T00:00:00Z